Developing vaccines to protect against infections from Ehrlichia and Anaplasma bacteria
Vaccines Against Ehrlichia and Anaplasma Species Infections
This study is working on developing safe and effective vaccines to help protect people and dogs from infections caused by certain tick-borne germs, so that we can better prevent these illnesses and improve how we diagnose them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10884288 on NIH RePORTER |
What this research studies
This research focuses on creating effective vaccines to combat infections caused by Ehrlichia and Anaplasma species, which are significant tick-borne pathogens affecting both humans and dogs. The approach involves genetic modifications of these bacteria to create weakened strains that can stimulate a strong immune response without causing disease. By studying how these pathogens evade the immune system, the research aims to develop vaccines that can provide long-lasting protection against these infections. Patients may benefit from improved diagnostic methods and preventive measures against these diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of tick-borne infections, particularly those living in endemic areas or with a history of exposure to ticks.
Not a fit: Patients who are not at risk of tick-borne diseases or those who have already been diagnosed with chronic infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce the incidence of tick-borne infections in humans and dogs.
How similar studies have performed: Previous research has shown promise in developing vaccines against similar tick-borne pathogens, indicating a potential for success in this area.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Ganta, Roman R. — University of Missouri-Columbia
- Study coordinator: Ganta, Roman R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.